{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:19:34Z","timestamp":1772824774311,"version":"3.50.1"},"publisher-location":"Boston, MA","reference-count":53,"publisher":"Springer US","isbn-type":[{"value":"9781461371809","type":"print"},{"value":"9781461548119","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999]]},"DOI":"10.1007\/978-1-4615-4811-9_5","type":"book-chapter","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T14:51:56Z","timestamp":1316098316000},"page":"35-46","source":"Crossref","is-referenced-by-count":24,"title":["Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP)"],"prefix":"10.1007","author":[{"given":"E.","family":"Wattel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Solary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hecquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ifrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Janvier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Rochant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Dreyfus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Veil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Hoang-Ngoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Stoppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gratecos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sadoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lioure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Desablens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Abgrall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leporrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Dupriez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Guyotat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/hon.2900060405","volume":"6","author":"P Martiat","year":"1988","unstructured":"Martiat P., Ferrant A., Michaux J.L., Sokal G. (1988); Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hematol Oncol, 6: 299\u2013305.","journal-title":"Hematol Oncol"},{"key":"5_CR2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood.V65.6.1364.bloodjournal6561364","volume":"65","author":"SD Michels","year":"1985","unstructured":"Michels SD., McKenna RW., Arthur DC., Brunning RD. (1985) Therapy related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood, 65: 1364\u20131372.","journal-title":"Blood"},{"key":"5_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2141.1989.tb07650.x","volume":"72","author":"CF Hoyle","year":"1989","unstructured":"Hoyle C.F., De Bastos M., Wheatley K., Sherrington P.D., Fischer P.J., Rees J.K.H., Gray R., Hayhoe F.G.J. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC\u2019s 9th AML trial. Br J Haematol, 72: 45\u201353.","journal-title":"Br J Haematol"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/1097-0142(19900901)66:5<831::AID-CNCR2820660503>3.0.CO;2-E","volume":"66","author":"T Witte De","year":"1990","unstructured":"De Witte T., Muus P., De Pauw B., Haanen C (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer, 66, 831\u2013837.","journal-title":"Cancer"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2141.1991.tb08616.x","volume":"77","author":"P Fenaux","year":"1991","unstructured":"Fenaux P., Morel P., Rose C, Lai J.L., Jouet J.P., Bauters F. (1991). Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol, 77, 497\u2013501.","journal-title":"Br J Haematol"},{"key":"5_CR6","first-page":"1805","volume":"9","author":"T Witte De","year":"1995","unstructured":"De Witte T., Suciu S., Peetermans M., Fenaux P., Strijckmans P., Hayat M., Jaksic J., Selleslag D., Zittoun R., Dardenne M., Solbu G., Zwierzina H., Muus P. (1995) A pilot study of intensive chemotherapy for bad prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805\u20131811.","journal-title":"Leukemia"},{"issue":"1","key":"5_CR7","first-page":"1960","volume":"82","author":"S Berstein","year":"1993","unstructured":"Berstein S., Brunetto V., Davey F., Mayer RJ., Wurster-Hill D., Schiffer C., Bloomfield C. (1993) Intensive chemotherapy for patients with myelodysplastic syndromes. Blood, 82, (suppl 1), 1960.","journal-title":"Blood"},{"issue":"suppl. 1","key":"5_CR8","first-page":"19","volume":"87","author":"T Ruutu","year":"1994","unstructured":"Ruutu T., H\u00e4nninen A., J\u00e4rventie G., Koistinen P., Koivunen E., K\u00e4tk\u00e4 K., Nousiainen T., Pelliniemi T.T., Remes K., Timonen T., Volin L., Elonen E. (1994) Intensive treatment of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia subsequent to MDS with idarubicin and cytarabine (abstract). Br J Haematol, 87(suppl. 1): 19.","journal-title":"Br J Haematol"},{"issue":"suppl 2","key":"5_CR9","first-page":"A138","volume":"70","author":"C Aul","year":"1995","unstructured":"Aul C., Runde V., Germing U., Burk M., Heyll A., Hildebrandt B., Willers R. (1995) Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy. Ann Hematol, 70(suppl 2), A138.","journal-title":"Ann Hematol"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0145-2126(94)90174-0","volume":"18","author":"C Aul","year":"1994","unstructured":"Aul C., Runde V., Gattermann N., Germing U., Schneider W., (1994) Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: results in 76 patients. Leuk Res, 18, suppl: 22 (abstr).","journal-title":"Leuk Res"},{"issue":"suppl II","key":"5_CR11","first-page":"A109","volume":"70","author":"W Hiddemann","year":"1995","unstructured":"Hiddemann W., B\u00fcchner T., W\u00f6rmann B., Koch P., Aul C., Balleisen L., Bennet J. (1995) Intensive therapy of high risk myelodysplastic syndromes with sequential intermediate dose cytosine arabinoside and mitox-antrone with or without GM-CSF (abstract). Ann Hematol, 70(suppl II): A109.","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"5_CR12","first-page":"339a","volume":"86","author":"SD Gore","year":"1995","unstructured":"Gore S.D., Burke P.J. (1995) Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy (abstract). Blood, 86(suppl 1): 339a.","journal-title":"Blood"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1046\/j.1365-2141.1997.2973114.x","volume":"98","author":"E Wattel","year":"1997","unstructured":"Wattel E., de Botton S., La\u00ef J.L., Preudhomme C., Lepelley P., Bauters F., Fenaux P. (1997). Long term follow up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long survivors and outcome of partial responders. Br J Haematol, 98, 983\u2013991.","journal-title":"Br J Haematol"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.leu.2400536","volume":"11","author":"C Gardin","year":"1997","unstructured":"Gardin C., Chaibi P., de Revel T., Rousselot P., Turlure P., Micl\u00e9a J.M., N\u00e9dellec G., Dombret H. (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia, 11: 16\u201321.","journal-title":"Leukemia"},{"key":"5_CR15","first-page":"998","volume":"8","author":"P Lepelley","year":"1994","unstructured":"Lepelley P., Soenen V., Preudhomme C., Lai J.L., Cosson A., Fenaux P. (1994). Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 8, 998\u20131004.","journal-title":"Leukemia"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ijc.2910620309","volume":"62","author":"S Bennis","year":"1995","unstructured":"Bennis S., Ichas F., Robert J. (1995). Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Int J Cancer, 62, 283\u2013290.","journal-title":"Int J Cancer"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/BF00685114","volume":"27","author":"RT Dorr","year":"1991","unstructured":"Dorr R.T., Liddil J.D. (1991). Modulation of mitomycin C-induced multidrug resistance in vitro. Cancer Chemother Pharmacol, 27, 290\u2013294.","journal-title":"Cancer Chemother Pharmacol"},{"key":"5_CR18","first-page":"160","volume":"8","author":"P Genne","year":"1994","unstructured":"Genne P., Duchamp O., Solary E., Pinard D., Belon J.P., Dimanche-Boitrel M.T., Chauffert B. (1994). Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562\/ADM. Leukemia, 8, 160\u2013164.","journal-title":"Leukemia"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/10428199609054853","volume":"23","author":"R Malayeri","year":"1996","unstructured":"Malayeri R., Filipits M., Suchomel R.W., Z\u2019chbauer S., Lechner K., Pirker R. (1996). Multidrug resistance in leukemias and its reversal. Leuk Lymphoma, 23, 451\u2013458.","journal-title":"Leuk Lymphoma"},{"key":"5_CR20","first-page":"361","volume":"32","author":"E Solary","year":"1990","unstructured":"Solary E., Velay I., Chauffert B., Caillot D., Bidan J.M., Dumas M., Casasnovas O., Guy H. (1990). Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562\/DXR. Nouv Rev Fr Hematol, 32, 361\u2013363.","journal-title":"Nouv Rev Fr Hematol"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/0959-8049(96)00054-8","volume":"6","author":"P Sonneveld","year":"1996","unstructured":"Sonneveld P. (1996). Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Eur J Cancer, 6, 1062\u20131069.","journal-title":"Eur J Cancer"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0005-2736(94)90272-0","volume":"1189","author":"PW Wigler","year":"1994","unstructured":"Wigler P.W., Patterson F.K. (1994). Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta, 1189, 1\u20136.","journal-title":"Biochim Biophys Acta"},{"key":"5_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF01203070","volume":"122","author":"IK Pajeva","year":"1996","unstructured":"Pajeva I.K., Wiese M., Cordes H.P., Seydel J.K. (1996). Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. J Cancer Res Clin Oncol, 122, 27\u201340.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5_CR24","first-page":"592","volume":"5","author":"E Solary","year":"1991","unstructured":"Solary E., Bidan J.M., Calvo F., Chauffert B., Caillot D., Mugneret F., Gauville C., Tsuruo T., Carli P.M., Guy H. (1991a). P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia, 5, 592\u201359","journal-title":"Leukemia"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/1097-0142(19911015)68:8<1714::AID-CNCR2820680811>3.0.CO;2-2","volume":"68","author":"E Solary","year":"1991","unstructured":"Solary E., Velay I., Chauffert B., Bidan J.M., Caillot D., Dumas M., Guy H. (1991b). Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562\/ ADM. Cancer, 68, 1714\u20131719.","journal-title":"Cancer"},{"key":"5_CR26","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1200\/JCO.1992.10.11.1730","volume":"10","author":"E Solary","year":"1992","unstructured":"Solary E., Caillot D., Chauffert B., Casasnovas R.O., Dumas M., Maynadie M., Guy H. (1992). Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol, 10, 1730\u20131736.","journal-title":"J Clin Oncol"},{"key":"5_CR27","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V88.4.1198.bloodjournal8841198","volume":"88","author":"E Solary","year":"1996","unstructured":"Solary E., Witz B., Caillot D., Moreau P., Desablens B., Cahn J.Y., Sadoun A., Pignon B., Berthou C., Maloisel F., Guyotat D., Casassus, P, Ifrah N., Lamy Y., Audhuy B., Colombat P., Harousseau J.L. (1996). Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood, 88, 1198\u20131205.","journal-title":"Blood"},{"key":"5_CR28","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V86.6.2329.bloodjournal8662329","volume":"86","author":"CP Leith","year":"1995","unstructured":"Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E., Weick J.K., Willman C.L. (1995). Correlation of multidrug resistance (MDR1) protein expression with functional dye\/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-\/efflux+ and MDR1 +\/efflux-cases. Blood, 86, 2329\u20132342.","journal-title":"Blood"},{"key":"5_CR29","first-page":"1315","volume":"7","author":"P Morel","year":"1993","unstructured":"Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E., Bauters F., Fenaux P. (1993). Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315\u20131323.","journal-title":"Leukemia"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z","volume":"66","author":"Y Kuwazuru","year":"1990","unstructured":"Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., Akiyama S. (1990). Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer, 66, 868\u2013873.","journal-title":"Cancer"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1365-2141.1994.tb08305.x","volume":"87","author":"P Wood","year":"1994","unstructured":"Wood P., Burgess R., MacGregor A., Yin J.A. (1994). P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol, 87, 509\u2013514.","journal-title":"Br J Haematol"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1365-2141.1990.tb04346.x","volume":"75","author":"H Sato","year":"1990","unstructured":"Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., et al. (1990). MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol, 75, 340\u2013345.","journal-title":"Br J Haematol"},{"key":"5_CR33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V79.2.473.473","volume":"79","author":"L Campos","year":"1992","unstructured":"Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. (1992). Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79, 473\u2013476.","journal-title":"Blood"},{"key":"5_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/10428199209051005","volume":"8","author":"JP Marie","year":"1992","unstructured":"Marie J.P., Legrand O., Russo D., Zhou D., Suberville A.M., Zittoun R. (1992). Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis. Leuk Lymphoma, 8, 261\u2013265.","journal-title":"Leuk Lymphoma"},{"key":"5_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s002770050147","volume":"72","author":"S Hegewisch-Becker","year":"1996","unstructured":"Hegewisch-Becker S., Hossfeld D.K. (1996). The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Ann Hematol, 72, 105\u2013117.","journal-title":"Ann Hematol"},{"key":"5_CR36","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood.V85.8.2147.bloodjournal8582147","volume":"85","author":"A Guerci","year":"1995","unstructured":"Guerci A., Merlin J.L., Missoum N., Feldmann L., Marchai S., Witz F., Rose C., Guerci O. (1995). Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 85, 2147\u20132153.","journal-title":"Blood"},{"key":"5_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/83.10.708","volume":"83","author":"R Pirker","year":"1991","unstructured":"Pirker R., Wallner J., Geissler K., Linkesch W., Haas O.A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., et al. (1991). MDR1 gene expression and treatment outcome in acute myeloid leukemia [see comments]. J Natl Cancer Inst, 83, 708\u2013712.","journal-title":"J Natl Cancer Inst"},{"key":"5_CR38","first-page":"974","volume":"8","author":"S Z\u00f6chbauer","year":"1994","unstructured":"Z\u00f6chbauer S., Gsur A., Brunner R., Kyrle P.A., Lechner K., Pirker R. (1994). P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia, 8, 974\u2013977.","journal-title":"Leukemia"},{"key":"5_CR39","first-page":"937","volume":"10","author":"AF List","year":"1996","unstructured":"List A.F. (1996). Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia, 10, 937\u2013942.","journal-title":"Leukemia"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1046\/j.1365-2141.1997.d01-2095.x","volume":"96","author":"SL McKenna","year":"1997","unstructured":"McKenna S.L., Padua R.A. (1997). Multidrug resistance in leukaemia. BrJ Haematol, 96, 659\u201374.","journal-title":"BrJ Haematol"},{"key":"5_CR41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/BF00689051","volume":"36","author":"O Gonzalez","year":"1995","unstructured":"Gonzalez O., Colombo T., De Fusco M., Imperatori L., Zucchetti M., D\u2019Incalci M. (1995). Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol, 36, 335\u201340.","journal-title":"Cancer Chemother Pharmacol"},{"key":"5_CR42","first-page":"1741","volume":"10","author":"P Sonneveld","year":"1996","unstructured":"Sonneveld P., Marie J.P., Huisman C., Vekhoff A., Schoester M., Faussat A.M., van Kapel J., Groenewegen A., Charnick S., Zittoun R., L\u2019wenberg, B (1996). Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia, 10, 1741\u20131750.","journal-title":"Leukemia"},{"key":"5_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/10428199509059671","volume":"19","author":"D Weber","year":"1995","unstructured":"Weber D., Dimopoulos M., Sinicrope F., Alexanian R. (1995). VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma, 19, 159\u2013163.","journal-title":"Leuk Lymphoma"},{"key":"5_CR44","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.1993.11.9.1652","volume":"11","author":"AF List","year":"1993","unstructured":"List A.F., Spier C., Greer J., Wolff S., Hutter J., Dorr R., Salmon S., Futscher B., Baier M., Dalton W. (1993). Phase I\/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia [see comments]. J Clin Oncol, 11, 1652\u201360.","journal-title":"J Clin Oncol"},{"key":"5_CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.1991.9.1.17","volume":"9","author":"TP Miller","year":"1991","unstructured":"Miller T.P., Grogan T.M., Dalton W.S., Spier C.M., Scheper R.J., Salmon S.E. (1991). P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol, 9, 17\u201324.","journal-title":"J Clin Oncol"},{"key":"5_CR46","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.1995.13.8.1995","volume":"13","author":"WH Wilson","year":"1995","unstructured":"Wilson W.H., Bates S.E., Fojo A., Bryant G., Zhan Z., Regis J., Wittes R.E., Jaffe E.S., Steinberg S.M., Herdt J., et a. (1995). Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol, 13, 1995\u20132004.","journal-title":"J Clin Oncol"},{"key":"5_CR47","first-page":"2797","volume":"52","author":"P Genne","year":"1992","unstructured":"Genne P., Dimanche-Boitrel M.T., Mauvernay R.Y., Gutierrez G., Duchamp O., Petit J.M., Martin F., Chauffert B. (1992). Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res, 52, 2797\u20132801.","journal-title":"Cancer Res"},{"key":"5_CR48","first-page":"S39","volume":"10","author":"J Beck","year":"1996","unstructured":"Beck J., Niethammer D., Gekeler V. (1996). MDR1, MRP, topoisomerase IIalpha\/beta, and cyclin A gene expression in acute and chronic leukemias. Leukemia, 10, S39\u2013S45.","journal-title":"Leukemia"},{"key":"5_CR49","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3109\/10428199809050914","volume":"29","author":"P Lepelley","year":"1998","unstructured":"Lepelley P., Grardel N., Preudhomme C., Wattel E., Cosson A., Fenaux P. (1998). Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS). Leuk Lymphoma, 29, 547\u2013551.","journal-title":"Leuk Lymphoma"},{"key":"5_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bjc.1990.262","volume":"62","author":"J Holmes","year":"1990","unstructured":"Holmes J., Wareing C., Jacobs A., Hayes J.D., Padua R.A., Wolf C.R. (1990). Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data. Br J Cancer, 62, 209\u2013212.","journal-title":"Br J Cancer"},{"key":"5_CR51","first-page":"1177","volume":"10","author":"F Gieseler","year":"1996","unstructured":"Gieseler F., Glasmacher A., K\u2030mpfe D., Wandt H., Nuessler V., Valsamas S., Kunze J., Wilms K. (1996). Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia, 10, 1177\u20131180.","journal-title":"Leukemia"},{"key":"5_CR52","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos, L., Rouault, J.P, Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J.P & Guyotat, D. (1993). High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091\u20133096.","journal-title":"Blood"},{"key":"5_CR53","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","volume":"84","author":"E Wattel","year":"1994","unstructured":"Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. & Fenaux, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148\u20133157.","journal-title":"Blood"}],"container-title":["Advances in Experimental Medicine and Biology","Drug Resistance in Leukemia and Lymphoma III"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4615-4811-9_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T19:45:33Z","timestamp":1592941533000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4615-4811-9_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999]]},"ISBN":["9781461371809","9781461548119"],"references-count":53,"URL":"https:\/\/doi.org\/10.1007\/978-1-4615-4811-9_5","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999]]}}}